GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fangzhou Inc (HKSE:06086) » Definitions » ROE %

Fangzhou (HKSE:06086) ROE % : 0.00% (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Fangzhou ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Fangzhou's annualized net income for the quarter that ended in Dec. 2023 was HK$-430 Mil. Fangzhou's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was HK$-1,995 Mil. Therefore, Fangzhou's annualized ROE % for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Fangzhou's ROE % or its related term are showing as below:

HKSE:06086's ROE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 4.73
* Ranked among companies with meaningful ROE % only.

Fangzhou ROE % Historical Data

The historical data trend for Fangzhou's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fangzhou ROE % Chart

Fangzhou Annual Data
Trend Dec21 Dec22 Dec23 Dec24
ROE %
- - - -

Fangzhou Semi-Annual Data
Dec21 Dec22 Dec23 Dec24
ROE % - - - -

Competitive Comparison of Fangzhou's ROE %

For the Pharmaceutical Retailers subindustry, Fangzhou's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fangzhou's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fangzhou's ROE % distribution charts can be found below:

* The bar in red indicates where Fangzhou's ROE % falls into.


;
;

Fangzhou ROE % Calculation

Fangzhou's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-215.243/( (-1909.479+-2079.78)/ 2 )
=-215.243/-1994.6295
=N/A %

Fangzhou's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-430.486/( (-1909.479+-2079.78)/ 2 )
=-430.486/-1994.6295
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Fangzhou  (HKSE:06086) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-430.486/-1994.6295
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-430.486 / 5325.19)*(5325.19 / 574.8515)*(574.8515 / -1994.6295)
=Net Margin %*Asset Turnover*Equity Multiplier
=-8.08 %*9.2636*N/A
=ROA %*Equity Multiplier
=-74.85 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-430.486/-1994.6295
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-430.486 / -430.316) * (-430.316 / -58.658) * (-58.658 / 5325.19) * (5325.19 / 574.8515) * (574.8515 / -1994.6295)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0004 * 7.336 * -1.1 % * 9.2636 * N/A
=N/A %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Fangzhou ROE % Related Terms

Thank you for viewing the detailed overview of Fangzhou's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fangzhou Business Description

Traded in Other Exchanges
N/A
Address
4th Street, Floor 1-2, Building S, Kehui Jingu, No. 99, Science Avenue, Luogang Science City, Huangpu District, Guangdong Province, Guangzhou, CHN
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
Executives
Asia Tech Holdings Limited 2201 Interest of corporation controlled by you
Vistra Trust (hong Kong) Limited 2301 Trustee
Crescent China Investment Management Ltd. 2102 Investment manager
Hand David Mckee 2201 Interest of corporation controlled by you
Rojanavanichkul Danai 2201 Interest of corporation controlled by you
Veneto Holdings Ltd. 2201 Interest of corporation controlled by you
Tech-med Cayman Iii Ltd. 2201 Interest of corporation controlled by you
Tech-med Investments (s) Pte. Ltd. 2101 Beneficial owner
Cp Pharmatech Singapore Pte. Ltd. 2101 Beneficial owner
Asia Tech Investments Ltd. 2101 Beneficial owner
Crescent Acso Investment Management Ltd 2201 Interest of corporation controlled by you
Crescent Trident Singapore Pte. Ltd. 2101 Beneficial owner
Xie Fangmin 2201 Interest of corporation controlled by you
Zhou Feng 2201 Interest of corporation controlled by you
Fangrong Management Limited 2101 Beneficial owner

Fangzhou Headlines

No Headlines